title: Adverse events during the titration phase of interferon-beta in remitting-relapsing multiple sclerosis are not predicted by body mass index nor by pharmacodynamic biomarkers.
abstract: BACKGROUND
  This study aimed to correlate body mass index or biomarkers with the frequency of common adverse events (AEs) with subcutaneous IFN β-1a during treatment titration in patients with relapsing-remitting multiple sclerosis previously naïve to IFN β.
  
  
  METHODS
  Eighty-four patients (66.3% females) were followed up during 8 weeks, 25.3% were overweight and 14.5% were obese.
  
  
  RESULTS
  Biomarkers steadily increased during all study period by 45.3% for β2-microglobulin, 262.8% for olygoadenylate synthetase-1, and 92.8% for neopterin. Overall AE reporting did not vary with the dose or treatment duration.
  
  
  CONCLUSIONS
  BMI was not predictive of increased risk for AEs. Biomarkers did not discriminate on the frequency of any AE either.
authors.affiliation: Department of Neurology, Hospital Xeral-Cies, Pontevedra, Spain.
authors.forename: Delicias
authors.initials: D
authors.lastname: Muñoz
authors.forename: Antonio
authors.initials: A
authors.lastname: Escartín
authors.forename: Dolores
authors.initials: D
authors.lastname: Dapena
authors.forename: Francisco
authors.initials: F
authors.lastname: Coret
authors.forename: Dionisio
authors.initials: D
authors.lastname: Fernández-Uría
authors.forename: Domingo
authors.initials: D
authors.lastname: Pérez
authors.forename: Bonaventura
authors.initials: B
authors.lastname: Casanova
authors.forename: Cristina
authors.initials: C
authors.lastname: Guijarro-Castro
authors.forename: Elvira
authors.initials: E
authors.lastname: Munteis
authors.forename: María
authors.initials: M
authors.lastname: del-Campo Amigo
authors.forename: Robustiano
authors.initials: R
authors.lastname: Pego
authors.forename: Carmen
authors.initials: C
authors.lastname: Calles
authors.forename: César
authors.initials: C
authors.lastname: García-Rey
authors.forename: Nuria
authors.initials: N
authors.lastname: Monsalve
authors.forename: David
authors.initials: D
authors.lastname: Sánchez-Matienzo
mesh_terms: D015088:2',5'-Oligoadenylate Synthetase / Q000378:metabolism; D015992:Body Mass Index; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects*; D016899:Interferon-beta / Q000009:adverse effects*; D053208:Kaplan-Meier Estimate; D008297:Male; D020528:Multiple Sclerosis, Chronic Progressive / Q000188:drug therapy*; D019798:Neopterin / Q000378:metabolism; D011237:Predictive Value of Tests; D012189:Retrospective Studies; D016896:Treatment Outcome; D001613:beta 2-Microglobulin / Q000378:metabolism
chemical_list: D007155:Immunologic Factors; D001613:beta 2-Microglobulin; D019798:Neopterin; D016899:Interferon-beta; C475085:OAS1 protein, human; D015088:2',5'-Oligoadenylate Synthetase